Heavy weight! 93 key projects of Zhangjiang Science City were signed, and the headquarters of ImmuneOnco was listed as one of the key projects

On the morning of December 18, 2020, the signing and launching ceremony of key projects of Zhangjiang Science City will be held in Zhangjiang. Focusing on the online new economy, the event focused on the three major industries of integrated circuit, biomedi......

2020-12-18

The patent of CD47xPD-L1 bispecific antibody was authorized by US patent office

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the self-developed bispecific antibody drug (Project No.: IMM2505) targeting both CD47 and PD-L1 was recently authorized by the U.S. Patent Office (application No.: 16/170024). The invention ......

2020-12-15

Clinical trial study on expanding new indications of IMM01 project

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (project number: IMM01) in China was accepted by NMPA for clinical trial application (IND) for new indications (MM, AML and MDS). This is......

2020-11-21

The patent of IMM0306 of ImmuneOnco was authorized by China Intellectual Property Office

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the IMM0306 project of the company has recently obtained the invention patent authorization of the China Intellectual Property Office (China patent application No.: CN201710151979.6). Meanwhi......

2020-09-15

The fifth anniversary of ImmuneOnco and the completion ceremony of the antibody drug research and development center were held successfully

On July 31, 2020, the fifth anniversary of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. and the completion ceremony of antibody drug R & D center were successfully held in building 47, Lane 908, Ziping road. ImmuneOnco Biopharmaceuticals (Shanghai......

2020-08-05